Repositorio Dspace

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Mostrar el registro sencillo del ítem

dc.contributor.author Barragán, Eva
dc.contributor.author Gil, José-Vicente
dc.contributor.author Ayala, Rosa
dc.contributor.author Chillón, Carmen
dc.contributor.author Soria, Elena
dc.contributor.author Bilbao, Cristina
dc.contributor.author Larrayoz, María-José
dc.contributor.author Prados-de-la-Torre, Esther
dc.contributor.author Solana, Antonio
dc.contributor.author Martínez-Cuadrón, David
dc.contributor.author Rodríguez-Veiga, Rebeca
dc.contributor.author Rodríguez-Arboli, Eduardo
dc.contributor.author Tormo, Mar
dc.contributor.author Martínez, Pilar
dc.contributor.author Lavilla, Esperanza
dc.contributor.author García-Garay, María-Del-Carmen
dc.contributor.author Arce, Olga
dc.contributor.author Bergua, Juan
dc.contributor.author Serrano, Josefina
dc.contributor.author Botella-Martínez, Carmen
dc.contributor.author Lacalzada, Carolina
dc.contributor.author Almela-Gallego, Agata
dc.contributor.author López-Lorenzo, José-Luis
dc.contributor.author Valero, Marta
dc.contributor.author Ibáñez, Francisco
dc.contributor.author Foncillas, María-Angeles
dc.contributor.author Rodríguez-Medina, Carlos
dc.contributor.author Olave, María-Teresa
dc.contributor.author Gómez-Correcha, Karol-Giovanna
dc.contributor.author Calderon, María-Teresa
dc.contributor.author Bernal, Teresa
dc.contributor.author Labrador, Jorge
dc.contributor.author Oliva, Ana
dc.contributor.author Madrigal, María-Dolores
dc.contributor.author Hermosin, Lourdes
dc.contributor.author Amador, Lourdes
dc.contributor.author García-Belmonte, Daniel
dc.contributor.author Herrera, Pilar
dc.contributor.author Vives, Susana
dc.contributor.author Pérez-Encinas, Manuel
dc.contributor.author Algarra, Lorenzo
dc.contributor.author Casado, Soledad
dc.contributor.author Martínez-Chamorro, Carmen
dc.contributor.author Polo, Marta
dc.contributor.author Balerdi, Amaia
dc.contributor.author Roldan, Alicia
dc.contributor.author Couto, Carmen
dc.contributor.author Pereiro, María
dc.contributor.author Vanegas, Raúl
dc.contributor.author Llop, Marta
dc.contributor.author Sargas, Claudia
dc.contributor.author Cionfrini, Antonia
dc.contributor.author Mendizábal, Yolanda
dc.contributor.author Sánchez, Joaquín
dc.contributor.author Calasanz, María-José
dc.contributor.author Gómez-Casares, María-Teresa
dc.contributor.author Pérez-Simon, José-Antonio
dc.contributor.author García-Sanz, Ramón
dc.contributor.author Martínez-López, Joaquín
dc.contributor.author Montesinos, Pau
dc.date.accessioned 2026-09-17T12:15:26Z
dc.date.available 2026-09-17T12:15:26Z
dc.date.issued 2026-08
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/28125
dc.description.abstract The 2024 European LeukemiaNet (ELN 2024) genetic risk classification was proposed to assess prognosis in patients with acute myeloid leukemia (AML) receiving less-intensive hypomethylating agent (HMA)-based regimens. However, its applicability to real-world patients remains unclear. We retrospectively analyzed 669 adult patients with AML from the PETHEMA registry treated in routine practice with HMA monotherapy (n = 414) or HMA-venetoclax (VEN) (n = 255). Molecular profiling was performed centrally among the Programa Español de Tratamientos en Hematología (PETHEMA) laboratory network. Median age was 75 years, and 48% had secondary AML (s-AML). Across the full cohort, ELN 2024 stratified patients into prognostic groups across both regimens, but overall survival (OS) was consistently shorter with HMA monotherapy than with HMA-VEN (median OS, 6.5 vs 11.2 months). Favorable risk patients treated with HMA-VEN achieved a median OS exceeding 18.4 months, whereas adverse risk patients had an OS of 7.7 months. ELN 2024 provides meaningful stratification in nonintensive AML, especially with HMA-VEN. However, prognostic accuracy is limited in HMA monotherapy and s-AML, particularly those arising from a myeloid neoplasm (sM-AML). Incorporating cytogenetic risk and sM-AML as adverse risk improved discrimination (area under the curve at 24 months, 0.71 vs 0.76). Refinement incorporating clinical history, cytogenetics, emerging mutations, and treatment response is needed to improve risk prediction in real-world populations.
dc.language.iso eng
dc.publisher ELSEVIER
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.title Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42294112
dc.relation.publisherversion https://linkinghub.elsevier.com/retrieve/pii/S295032802600049X
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1016/j.bneo.2026.100238
dc.journal.title BLOOD NEOPLASIA
dc.identifier.essn 2950-3280


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta